Share-based Payment Arrangement, Expense of Akebia Therapeutics, Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Akebia Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Akebia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $3,199,000, a 89% increase year-over-year.
  • Akebia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $11,283,000, a 45% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $11,283,000, a 45% increase from 2024.
  • Akebia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,775,000, a 17% decline from 2023.
  • Akebia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9,317,000, a 48% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Akebia Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $11,283,000 $3,199,000 +$1,502,000 +89% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $9,781,000 $3,221,000 +$1,575,000 +96% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $8,206,000 $2,676,000 +$604,000 +29% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,602,000 $2,187,000 -$173,000 -7.3% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $7,775,000 $1,697,000 +$183,000 +12% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $7,592,000 $1,646,000 -$178,000 -9.8% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $7,770,000 $2,072,000 -$1,418,000 -41% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $9,188,000 $2,360,000 -$129,000 -5.2% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $9,317,000 $1,514,000 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $1,824,000 -$1,531,000 -46% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $3,490,000 -$3,427,000 -50% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $2,489,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $3,355,000 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $6,917,000 01 Apr 2022 30 Jun 2022 10-Q 28 Aug 2023 2023 Q2
Q1 2021 $25,536,000 $5,992,000 +$1,076,000 +22% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $24,460,000 $6,088,000 +$1,154,000 +23% 01 Oct 2020 31 Dec 2020 10-K/A 28 Aug 2023 2022 FY
Q3 2020 $23,306,000 $6,592,000 +$3,979,000 +152% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $19,327,000 $6,864,000 +$4,580,000 +201% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $14,747,000 $4,916,000 +$2,822,000 +135% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $11,925,000 $4,934,000 -$7,128,000 -59% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $19,053,000 $2,613,000 +$361,000 +16% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $18,692,000 $2,284,000 -$210,000 -8.4% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $18,902,000 $2,094,000 -$138,000 -6.2% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q4 2018 $19,040,000 $12,062,000 +$9,869,000 +450% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $9,171,000 $2,252,000 +$99,000 +4.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $9,072,000 $2,494,000 -$11,000 -0.44% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $9,083,000 $2,232,000 -$3,197,000 -59% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $12,280,000 $2,193,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
Q3 2017 $2,153,000 +$525,000 +32% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,505,000 +$1,283,000 +105% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $5,429,000 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q3 2016 $1,628,000 +$466,000 +40% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2016 2016 Q3
Q2 2016 $1,222,000 +$127,000 +12% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2016 2016 Q2
Q4 2015 $4,714,000 $1,329,000 +$443,000 +50% 01 Oct 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
Q3 2015 $4,271,000 $1,162,000 -$73,000 -5.9% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $4,344,000 $1,095,000 -$349,000 -24% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $4,693,000 $1,128,000 -$1,317,000 -54% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q1
Q4 2014 $6,010,000 $886,000 -$239,948 -21% 01 Oct 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
Q3 2014 $6,249,948 $1,235,000 +$904,741 +274% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $5,345,207 $1,444,000 +$1,392,599 +2709% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $3,952,608 $2,445,000 +$2,388,608 +4236% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q4 2013 $1,564,000 $1,125,948 01 Oct 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
Q3 2013 $330,259 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $51,401 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $56,392 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1

Akebia Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,283,000 +$3,508,000 +45% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $7,775,000 -$1,542,000 -17% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $9,317,000 -$8,532,000 -48% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $17,849,000 -$4,886,000 -21% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $22,735,000 -$1,725,000 -7.1% 01 Jan 2021 31 Dec 2021 10-K/A 28 Aug 2023 2022 FY
2020 $24,460,000 +$12,535,000 +105% 01 Jan 2020 31 Dec 2020 10-K/A 28 Aug 2023 2022 FY
2019 $11,925,000 -$7,115,000 -37% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $19,040,000 +$6,760,000 +55% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $12,280,000 +$6,455,000 +111% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $5,825,000 +$1,111,000 +24% 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019 2018 FY
2015 $4,714,000 -$1,296,000 -22% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $6,010,000 +$4,446,000 +284% 01 Jan 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
2013 $1,564,000 +$1,442,000 +1182% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
2012 $122,000 01 Jan 2012 31 Dec 2012 10-K 04 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.